185:
128:
66:
25:
347:). Additional products include Songling xuemaikang capsules, Keluoxin capsules, Xinluona (Mosapride Citrate), Bolexin (Venlafaxine hydrochloride capsules) and Bosiqing (Aripiprazole tablets), Yitaning (Dexzopiclone tablets), Shugan Jieyu (capsules), Danshu (capsules), and Yiqing (capsules). Kanghong also currently has 13 subsidiaries in China, Israel, and the United States.
224:, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Knowledge.
210:
234:
38:
359:(AMD). In 2017, Kanghong acquired IOPtima, a subsidiary of BioLight Israeli Life Sciences Investment. Kanghong also became a distributor of IOPtima’s products in China.
374:
investments were approximately 29% of its annual revenue, and by 2020, the company held 238 patents and exclusive patents for 13 drugs out of their 18 products.
274:
148:
44:
244:
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
396:, Kanghong donated money, protective clothing, and other materials to medical institutions across China through the China Red Cross Foundation.
657:
418:
91:
252:
300:
166:
109:
52:
690:
356:
144:
80:
509:
137:
458:
377:
As of
December 2020, the company’s drugs in development are for treatment of various diseases and conditions including
710:
265:
Content in this edit is translated from the existing
Chinese Knowledge article at ]; see its history for attribution.
367:
371:
260:
337:
229:
382:
329:
325:
281:
480:
197:
76:
320:. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for
665:
426:
393:
256:
87:
333:
386:
609:
317:
686:
704:
355:
In 2005, Kanghong started development of the drug conbercept, which is used to treat
321:
419:"China Focus: Innovation boosts development of China's private medical companies"
143:
It may require cleanup to comply with
Knowledge's content policies, particularly
537:
481:"Chengdu Kanghong Pharma Solidifies Ownership of Israeli Medical Device Company"
450:
344:
585:
633:
561:
343:
As of May 2021, the company had 18 drugs on the market including
Lumitin (
363:
263:
to the source of your translation. A model attribution edit summary is
378:
316:
is a publicly traded pharmaceutical company based in the province of
451:"002773.SZ - Chengdu Kanghong Pharma Grp Co Ltd Profile | Reuters"
221:
178:
121:
59:
18:
510:"Chengdu Kanghong Pharma buys Israel's IOPtima for $ 56m"
233:
to this template: there are already 293 articles in the
136:
A major contributor to this article appears to have a
340:
with a market capitalization at around $ 6 billion.
217:
213:
a machine-translated version of the
Chinese article.
314:Chengdu Kanghong Pharmaceutical Group Co., Ltd.
259:accompanying your translation by providing an
204:Click for important translation instructions.
196:expand this article with text translated from
362:In 2016, Kanghong received approval from the
8:
94:of quality, and to make it neutral in tone.
53:Learn how and when to remove these messages
610:"康弘药业2020年研发投入同比增长21.26% 加快创新布局未来 _ 东方财富网"
301:Learn how and when to remove this message
167:Learn how and when to remove this message
110:Learn how and when to remove this message
405:
370:of conbercept. In 2020, the company’s
336:systems. The company is listed on the
238:
7:
532:
530:
504:
502:
500:
445:
443:
413:
411:
409:
687:"与"白衣战士""战"在一起 康弘药业又一批国际采购医用防护物资到位"
14:
34:This article has multiple issues.
693:from the original on 2021-06-24.
357:age-related macular degeneration
183:
147:. Please discuss further on the
126:
64:
23:
461:from the original on 2021-05-25
42:or discuss these issues on the
269:You may also add the template
1:
479:Baumer, Lilach (2018-09-27).
562:"康弘药业：能成为第二个恒瑞医药吗？ | 风云独立研报"
485:CTECH - www.calcalistech.com
241:will aid in categorization.
727:
216:Machine translation, like
381:, fundus disease tumors,
368:Phase III clinical trials
198:the corresponding article
455:www.reuters.comundefined
338:Shenzhen stock exchange
280:For more guidance, see
658:"康弘药业疫情大考中彰显责任与创新-新华网"
383:diabetic macular edema
271:{{Translated|zh|康弘药业}}
75:may be written from a
614:finance.eastmoney.com
586:"成都康弘药业集团股份有限公司_药智新闻"
538:"康弘药业亮相中国品牌日 | 北晚新视觉"
282:Knowledge:Translation
253:copyright attribution
145:neutral point of view
81:neutral point of view
634:"康弘药业迎难而上，开拓研发创新新版图"
16:Pharmaceutical Group
77:fan's point of view
711:Companies of China
261:interlanguage link
668:on April 17, 2020
662:www.xinhuanet.com
638:finance.ifeng.com
566:finance.ifeng.com
423:www.xinhuanet.com
394:COVID-19 pandemic
311:
310:
303:
293:
292:
205:
177:
176:
169:
140:with its subject.
120:
119:
112:
57:
718:
695:
694:
683:
677:
676:
674:
673:
664:. Archived from
654:
648:
647:
645:
644:
630:
624:
623:
621:
620:
606:
600:
599:
597:
596:
582:
576:
575:
573:
572:
558:
552:
551:
549:
548:
534:
525:
524:
522:
521:
506:
495:
494:
492:
491:
476:
470:
469:
467:
466:
447:
438:
437:
435:
434:
425:. Archived from
415:
387:Type II diabetes
306:
299:
272:
266:
240:
239:|topic=
237:, and specifying
222:Google Translate
203:
187:
186:
179:
172:
165:
161:
158:
152:
138:close connection
130:
129:
122:
115:
108:
104:
101:
95:
90:to conform to a
79:, rather than a
68:
67:
60:
49:
27:
26:
19:
726:
725:
721:
720:
719:
717:
716:
715:
701:
700:
699:
698:
685:
684:
680:
671:
669:
656:
655:
651:
642:
640:
632:
631:
627:
618:
616:
608:
607:
603:
594:
592:
584:
583:
579:
570:
568:
560:
559:
555:
546:
544:
542:www.takefoto.cn
536:
535:
528:
519:
517:
508:
507:
498:
489:
487:
478:
477:
473:
464:
462:
449:
448:
441:
432:
430:
417:
416:
407:
402:
353:
326:central nervous
307:
296:
295:
294:
289:
288:
287:
270:
264:
206:
188:
184:
173:
162:
156:
153:
142:
131:
127:
116:
105:
99:
96:
92:higher standard
85:
69:
65:
28:
24:
17:
12:
11:
5:
724:
722:
714:
713:
703:
702:
697:
696:
689:. 2020-03-09.
678:
649:
625:
601:
590:news.yaozh.com
577:
553:
526:
496:
471:
439:
404:
403:
401:
398:
352:
349:
318:Sichuan, China
309:
308:
291:
290:
286:
285:
278:
267:
245:
242:
230:adding a topic
225:
214:
207:
193:
192:
191:
189:
182:
175:
174:
134:
132:
125:
118:
117:
72:
70:
63:
58:
32:
31:
29:
22:
15:
13:
10:
9:
6:
4:
3:
2:
723:
712:
709:
708:
706:
692:
688:
682:
679:
667:
663:
659:
653:
650:
639:
635:
629:
626:
615:
611:
605:
602:
591:
587:
581:
578:
567:
563:
557:
554:
543:
539:
533:
531:
527:
515:
511:
505:
503:
501:
497:
486:
482:
475:
472:
460:
456:
452:
446:
444:
440:
429:on 2018-12-17
428:
424:
420:
414:
412:
410:
406:
399:
397:
395:
390:
388:
384:
380:
375:
373:
369:
365:
360:
358:
350:
348:
346:
341:
339:
335:
331:
327:
323:
319:
315:
305:
302:
283:
279:
276:
268:
262:
258:
254:
250:
246:
243:
236:
235:main category
232:
231:
226:
223:
219:
215:
212:
209:
208:
201:
199:
194:You can help
190:
181:
180:
171:
168:
160:
150:
146:
141:
139:
133:
124:
123:
114:
111:
103:
93:
89:
83:
82:
78:
73:This article
71:
62:
61:
56:
54:
47:
46:
41:
40:
35:
30:
21:
20:
681:
670:. Retrieved
666:the original
661:
652:
641:. Retrieved
637:
628:
617:. Retrieved
613:
604:
593:. Retrieved
589:
580:
569:. Retrieved
565:
556:
545:. Retrieved
541:
518:. Retrieved
516:. 2017-11-21
513:
488:. Retrieved
484:
474:
463:. Retrieved
454:
431:. Retrieved
427:the original
422:
391:
376:
361:
354:
342:
313:
312:
297:
257:edit summary
248:
228:
195:
163:
154:
135:
106:
97:
74:
50:
43:
37:
36:Please help
33:
392:During the
385:(DME), and
88:clean it up
672:2021-06-16
643:2021-05-27
619:2021-05-27
595:2021-05-27
571:2021-06-16
547:2021-06-16
520:2021-05-27
490:2021-05-27
465:2021-05-27
433:2021-05-27
400:References
345:conbercept
322:ophthalmic
200:in Chinese
39:improve it
366:to begin
334:endocrine
330:digestive
275:talk page
227:Consider
157:June 2021
149:talk page
100:June 2021
45:talk page
705:Category
691:Archived
459:Archived
364:U.S. FDA
251:provide
372:R&D
351:History
273:to the
255:in the
86:Please
514:Globes
379:glioma
218:DeepL
332:and
249:must
247:You
211:View
220:or
202:.
707::
660:.
636:.
612:.
588:.
564:.
540:.
529:^
512:.
499:^
483:.
457:.
453:.
442:^
421:.
408:^
389:.
328:,
324:,
48:.
675:.
646:.
622:.
598:.
574:.
550:.
523:.
493:.
468:.
436:.
304:)
298:(
284:.
277:.
170:)
164:(
159:)
155:(
151:.
113:)
107:(
102:)
98:(
84:.
55:)
51:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.